Neuronetics

Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results

Retrieved on: 
Tuesday, March 5, 2024
Social media, TMS, Transcranial magnetic stimulation, Telephone, Marketing, SSM Health, Webcast, Health, Neuronetics, Patient, Policy, Ferdinand Magellan, Knowledge, Psychotherapy

For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.

Key Points: 
  • For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.
  • Gross margin for the full year 2023 were 72.5%, a decrease of approximately 380 basis points from the full year 2022 gross margin of 76.3%.
  • Operating expenses during the full year 2023 was $82.3 million, a decrease of $2.5 million, or 2.9% compared to $84.8 million in the full year 2022.
  • See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss.

Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System

Retrieved on: 
Monday, February 12, 2024
Marketing, Quality of life, Patient, Transcranial magnetic stimulation, STIM, Health, Neuronetics, SVP

The update introduces features to streamline the way practices track and document status for their potential and current patients.

Key Points: 
  • The update introduces features to streamline the way practices track and document status for their potential and current patients.
  • "It's essential for healthcare providers to have the most recent technology that supports them in continuously improving patient care processes," stated Cory Anderson, SVP of R&D and Clinical.
  • All the features are designed to save practices time, allowing them to focus more on direct patient care rather than administrative tasks.
  • Another notable feature in this TrakStar release is a more robust Benefits Investigation report that provides practices with estimated patient financial responsibility prior to a patient beginning treatment.

Ecovyst Names Kara L. Thornton Vice President and Chief Human Resources Officer

Retrieved on: 
Tuesday, January 16, 2024
Senior, Human resources, Cabrini University, Bayer, Sun Pharma, Johnson & Johnson, Neuronetics, Human, Management

MALVERN, Pa., Jan. 16, 2024 /PRNewswire/ -- Ecovyst Inc. (NYSE: ECVT) ("Ecovyst" or the "Company"), a leading integrated and innovative global provider of advanced materials,specialty catalysts and services, today announced that Kara L. Thornton has been appointed Vice President and Chief Human Resources Officer.

Key Points: 
  • MALVERN, Pa., Jan. 16, 2024 /PRNewswire/ -- Ecovyst Inc. (NYSE: ECVT) ("Ecovyst" or the "Company"), a leading integrated and innovative global provider of advanced materials,specialty catalysts and services, today announced that Kara L. Thornton has been appointed Vice President and Chief Human Resources Officer.
  • "Our valued employees play a vital role in Ecovyst's ongoing success, and to ensure that our people strategy continues to align with the Company's overall goals, I am pleased to announce that Kara Thornton has joined Ecovyst as Vice President and Chief Human Resources Officer.
  • Kara's broad knowledge and expertise in the Human Resources field will help ensure that Ecovyst continues to attract, develop and retain the personnel and talent to advance our Company's strategic objectives," said Kurt J. Bitting, Ecovyst's Chief Executive Officer.
  • Ms. Thornton most recently service as Senior Vice President of Human Resources at Neuronetics, a medical device company based in Malvern, Pennsylvania.

Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory

Retrieved on: 
Monday, December 18, 2023
Neuronetics, Marketing, Quality of life, Food, FDA, TMS, HSS, Mental health, SVP, Patient, STIM, Medical device

This proprietary accessory, designed with versatility and provider convenience in mind, seamlessly integrates with both legacy and new NeuroStar systems and further enhances efficiency and patient experience.

Key Points: 
  • This proprietary accessory, designed with versatility and provider convenience in mind, seamlessly integrates with both legacy and new NeuroStar systems and further enhances efficiency and patient experience.
  • “The NeuroSite™ FDA clearance is the latest of many enhancements designed to improve the patient experience, exemplifying our ongoing commitment to continually advance medical technology for mental health,” stated Cory Anderson, SVP of R&D and Clinical.
  • “We are thrilled to introduce yet another innovative accessory to our suite of products that deliver a fast, easy, reliable treatment that both patients and providers trust.”
    By leveraging the patient's unique anatomical features, NeuroSite™ Coil Placement Accessory ensures precise and reproducible coil placement.
  • “This latest tool reinforces my confidence in providing consistent results and truly exceptional care to my patients.”
    NeuroSite™ will be available to all NeuroStar providers beginning in Q1 of 2024.

NeuroStar TMS Receives Expanded Regulatory Approval in Japan

Retrieved on: 
Monday, December 4, 2023
Neuronetics, Marketing, Quality of life, Partnership, Depression, Medication, TMS, MDSAP, DSM-IV codes, Health, MDD, Patient, Transcranial magnetic stimulation, STIM, Dash, PMDA

The features covered in this approval include the NeuroStar 3.7 platform, MT Cap , D-Tect ™ MT Accessory, and the Dash treatment protocol.

Key Points: 
  • The features covered in this approval include the NeuroStar 3.7 platform, MT Cap , D-Tect ™ MT Accessory, and the Dash treatment protocol.
  • The Dash treatment protocol reduces the daily TMS treatment time from 38 minutes to under 19 minutes.
  • NeuroStar TMS Therapy aims to fill this unmet need through its exclusive distribution partnership with Teijin Pharma Limited.
  • NeuroStar is advancing its global strategy and strengthening its global presence with recent announcements of regulatory approval in South Korea , as well as EU-MDR and MDSAP certifications.

NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements

Retrieved on: 
Monday, November 13, 2023
Attention, TMS, Data management, Patient, STIM, Practice management, Marketing, Workflow, Software, Neuronetics, Mental health, Quality of life, Health, SVP, Nursing

“These updates represent our goal to support NeuroStar devices throughout their operational lifespan and build a foundation for future improvements.

Key Points: 
  • “These updates represent our goal to support NeuroStar devices throughout their operational lifespan and build a foundation for future improvements.
  • In addition to the NeuroStar software update, TrakStar’s software is upgraded to significantly enhance patient care and practice management.
  • These real-time notifications empower practices to swiftly identify patients who may require a follow-up NeuroStar treatment or clinical evaluation.
  • NeuroStar continually demonstrates that they are committed to best-in-class patient care and outcomes.”
    The NeuroStar software will be rolled out in phases during the 4th quarter, starting today.

Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage

Retrieved on: 
Thursday, November 9, 2023
Health policy, Policy, OH, MDD, TMS, STIM, Blue Cross Blue Shield Association, HI, Neuronetics, Major depressive disorder, DSM-IV codes, Psychotherapy, Criterion, OR, Quality of life, Marketing, Aetna, Transcranial magnetic stimulation, BCBS, SSM Health, CO, Patient, Regenerative Medicine Advanced Therapy, Pharmaceutical industry, Health insurance, Ferdinand Magellan, UnitedHealth Group, MD

Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.

Key Points: 
  • Dean Health Plan has also removed the requirement for a prior trial of psychotherapy.
  • The policy updates from BCBS Kansas City and Dean Health Plan are effective immediately, with the Magellan update going into effect on November 18, 2023.
  • Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy changes.
  • For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .

HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS

Retrieved on: 
Wednesday, November 8, 2023
Therapy, Economics, Neuronetics, Eli Lilly, Eli Lilly and Company, CNS, MBA, HBA, R, BA, Growth, Albion College, Harmony, Bristol Myers Squibb, DSM-IV codes, Neurology, Healthcare Businesswomen's Association, Business, Parity, Indiana University, Patient, Pharmaceutical industry, Management, Lundbeck

PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.

Key Points: 
  • PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.
  • Anastasiou held various leadership positions at Lundbeck, where he was critical in shaping overall corporate strategy, R&D priorities, and business development.
  • "I am energized to join Harmony's Board of Directors at this critical stage of growth for the company.
  • "Peter's CNS and business development expertise will support Harmony's growth priorities," said Harmony Biosciences Chairman Jeff Aronin.

Neuronetics Reports Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, Social media, TMS, Neuronetics, EBITDA, Telephone, Health, Webcast, Transcranial magnetic stimulation, Patient, Cryptocurrency, Video game, Pharmaceutical industry

In the third quarter of 2023, U.S. treatment session revenue per active site was $11,917 compared to $11,364 in the third quarter of 2022.

Key Points: 
  • In the third quarter of 2023, U.S. treatment session revenue per active site was $11,917 compared to $11,364 in the third quarter of 2022.
  • Gross margin for the third quarter of 2023 was 65.8%, a decrease of approximately 1260 basis points from the third quarter of 2022 gross margin of 78.4%.
  • Operating expenses during the third quarter of 2023 were $20.6 million, an increase of $0.2 million, or 1%, compared to $20.4 million in the third quarter of 2022.
  • EBITDA for the third quarter of 2023 was $(7.7) million as compared to the third quarter of 2022 EBITDA of $(6.2) million.

GrayMatters Health Appoints Kirk Thelander as Chief Commercial Officer

Retrieved on: 
Wednesday, October 18, 2023
Therapy, EFP, Psychotherapy, Entrepreneurship, PTSD, Rasmus Thelander, Growth, GMH, Neuronetics, U.S. FDA, EEG, Nursing, Prism

HAIFA, Israel, Oct. 18, 2023 /PRNewswire/ -- GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental health care, today announced the appointment of Kirk Thelander to Chief Commercial Officer. Thelander joins GMH's expanding US-based executive team, bringing more than 17 years of experience in medical device sales and management, launching mental health technologies and bringing digital therapeutics to new markets.

Key Points: 
  • Executive with Robust Mental Health and Therapeutic Experience Joins GMH's Expanding US Executive Team, Supporting Prism for PTSD Rollout
    HAIFA, Israel, Oct. 18, 2023 /PRNewswire/ -- GrayMatters Health (GMH) , developer of digital self-neuromodulation therapies for mental health care, today announced the appointment of Kirk Thelander to Chief Commercial Officer.
  • Thelander joins GMH's expanding US-based executive team, bringing more than 17 years of experience in medical device sales and management, launching mental health technologies and bringing digital therapeutics to new markets.
  • Mr. Thelander joins GMH from previous leadership roles at AloeMD, LLC, Greenbrook TMS NeuroHealth Centers, Freespira and Neuronetics, Inc.
  • In his role at GMH, Thelander will be responsible for developing and executing commercial strategies aimed at accelerating growth.